Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1978 1
1983 3
1988 1
1989 1
1994 2
1997 1
2000 1
2003 1
2005 2
2006 2
2009 3
2011 1
2012 1
2016 3
2017 1
2018 1
2019 1
2020 1
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M, Chiu MN, Pilkhwal Sah S. Bhardwaj M, et al. Cutan Ocul Toxicol. 2022 Mar;41(1):73-90. doi: 10.1080/15569527.2022.2034842. Epub 2022 Feb 20. Cutan Ocul Toxicol. 2022. PMID: 35107396 Review.
The mechanism of signalling of anti-PD-1/PD-L1 involves triggering cytotoxic CD4+/CD8 + T cell activation and subsequent abolition of cancer cells which induces specific immunologic adverse events that are specific to these therapies. ...The search mainly involved r …
The mechanism of signalling of anti-PD-1/PD-L1 involves triggering cytotoxic CD4+/CD8 + T cell activation and subsequent abolition of cancer …
Cutaneous lupus erythematosus: issues in diagnosis and treatment.
Walling HW, Sontheimer RD. Walling HW, et al. Am J Clin Dermatol. 2009;10(6):365-81. doi: 10.2165/11310780-000000000-00000. Am J Clin Dermatol. 2009. PMID: 19824738 Review.
Cutaneous lupus erythematosus (LE) may present in a variety of clinical forms. Three recognized subtypes of cutaneous LE are acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), and chronic cutaneous LE (CCLE). ...
Cutaneous lupus erythematosus (LE) may present in a variety of clinical forms. Three recognized subtypes of cutaneou …
Recent Developments in the Diagnosis and Management of Photosensitive Disorders.
Nahhas AF, Oberlin DM, Braunberger TL, Lim HW. Nahhas AF, et al. Am J Clin Dermatol. 2018 Oct;19(5):707-731. doi: 10.1007/s40257-018-0365-6. Am J Clin Dermatol. 2018. PMID: 29959757 Review.
Photodermatoses are broadly classified as immunologically mediated, chemical- and drug-induced, photoaggravated, and genetic (defective DNA repair or chromosomal instability) diseases. ...
Photodermatoses are broadly classified as immunologically mediated, chemical- and drug-induced, photoaggravated, and genetic ( …
Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.
Otani IM, Banerji A. Otani IM, et al. Curr Allergy Asthma Rep. 2016 Mar;16(3):17. doi: 10.1007/s11882-016-0595-8. Curr Allergy Asthma Rep. 2016. PMID: 26810177 Review.
Delayed hypersensitivity reactions to PPIs have also been reported. Occupational exposures causing cutaneous reactions to PPIs are the most commonly reported delayed hypersensitivity reaction, followed by drug-induced subacute cutaneous lupus …
Delayed hypersensitivity reactions to PPIs have also been reported. Occupational exposures causing cutaneous reactions to PPIs are th …
Issues and advances in the management and pathogenesis of cutaneous lupus erythematosus.
Pelle MT. Pelle MT. Adv Dermatol. 2006;22:55-65. doi: 10.1016/j.yadr.2006.09.009. Adv Dermatol. 2006. PMID: 17249295 Review.
Evidence-based therapy for cutaneous lupus is lacking. A new clinical assessment tool for cutaneous lupus, the CLASI score, will enable more standardized assessments of response to therapy. ...Large, controlled trials are needed, not only …
Evidence-based therapy for cutaneous lupus is lacking. A new clinical assessment tool for cutaneous lupus …
Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome.
Deng Z, Guo A, Wu C, Wang C. Deng Z, et al. J Cosmet Dermatol. 2022 Dec;21(12):7202-7208. doi: 10.1111/jocd.15450. Epub 2022 Oct 31. J Cosmet Dermatol. 2022. PMID: 36214602
PURPOSE: Previous knowledge about the association between proton pump inhibitors (PPIs) exposure and subacute cutaneous lupus erythematosus (SCLE) was mainly based on limited case reports or few review studies. ...PPIs should be suspected when considering pos …
PURPOSE: Previous knowledge about the association between proton pump inhibitors (PPIs) exposure and subacute cutaneous lupus …
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
Osmani Z, Schrama TJ, Zacouris-Verweij W, Andersen J, Frankel S, Bultink IEM, Cornet A, van Vollenhoven RF. Osmani Z, et al. Lupus Sci Med. 2021 Mar;8(1):e000478. doi: 10.1136/lupus-2021-000478. Lupus Sci Med. 2021. PMID: 33795484 Free PMC article.
BACKGROUND: Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, 5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy. ...RESULTS: The online questionnaire was completed b …
BACKGROUND: Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, 5 years) and hi …
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, Pasoto SG. Yuki EFN, et al. J Clin Rheumatol. 2021 Sep 1;27(6):248-259. doi: 10.1097/RHU.0000000000001160. J Clin Rheumatol. 2021. PMID: 31693649 Review.
BACKGROUND: Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). Recently, lenalidomide has been also prescribed for SLE/CLE treatment. ...CONCLUSIONS: Thalidomide is very efficacious as an induction therapy for …
BACKGROUND: Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). Recently, len …
Early diagnosis and treatment of discoid lupus erythematosus.
Panjwani S. Panjwani S. J Am Board Fam Med. 2009 Mar-Apr;22(2):206-13. doi: 10.3122/jabfm.2009.02.080075. J Am Board Fam Med. 2009. PMID: 19264946 Free article.
Discoid lupus erythematosus is a chronic dermatological disease that can lead to scarring, hair loss, and hyperpigmentation changes in skin if it is not treated early and promptly. ...Potent topical steroids and antimalarials are the mainstay of treatment. Some case …
Discoid lupus erythematosus is a chronic dermatological disease that can lead to scarring, hair loss, and hyperpigmentation ch …
Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.
Cohen MG, Prowse MV. Cohen MG, et al. Med Toxicol Adverse Drug Exp. 1989 May-Jun;4(3):199-218. doi: 10.1007/BF03259997. Med Toxicol Adverse Drug Exp. 1989. PMID: 2490148 Review.
Arthropathy may be seen with several different syndromes, including drug-induced lupus erythematosus (DILE), serum sickness and gout. ...Rarely, polymyositis and scleroderma-like syndromes have been associated with drug therapy. Corticost …
Arthropathy may be seen with several different syndromes, including drug-induced lupus erythematosus (DILE), ser …
31 results